Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

ClinicalTrials.gov ID: NCT02877927

Public ClinicalTrials.gov record NCT02877927. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.

Study identification

NCT ID
NCT02877927
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Enrollment
735 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2016 (Type not available)
Primary completion
May 26, 2017 (Actual)
Completion
Jun 6, 2017 (Actual)
Last update posted
Nov 30, 2018

2016 – 2017

United States locations

U.S. sites
50
U.S. states
15
U.S. cities
39
Facility City State ZIP Site status
Site 620 Birmingham Alabama 35215 —
Site 642 Mobile Alabama 36608 —
Site 616 Anaheim California 92801 —
Site 601 Anaheim California 92804 —
Site 636 Bakersfield California 93301 —
Site 606 Buena Park California 90620 —
Site 604 Chula Vista California 91911 —
Site 659 Huntington Beach California 92647 —
Site 608 La Mesa California 91942 —
Site 618 Laguna Hills California 92653 —
Site 612 Long Beach California 90813 —
Site 648 Modesto California 95350 —
Site 610 Oceanside California 92056 —
Site 615 San Diego California 92114 —
Site 621 San Diego California 92119 —
Site 613 San Francisco California 94115 —
Site 603 Stockton California 95204 —
Site 650 Torrance California 90502 —
Site 646 Ventura California 93003 —
Site 614 DeLand Florida 32720 —
Site 655 Fort Myers Florida 33901 —
Site 656 Homestead Florida 33030 —
Site 631 Miami Florida 33015 —
Site 658 Miami Florida 33125 —
Site 654 Miami Florida 33134 —
Site 626 Miami Florida 33144 —
Site 637 Miami Florida 33144 —
Site 653 Miami Florida 33145 —
Site 641 Miami Florida 33175 —
Site 645 Miami Florida 33175 —
Site 640 Miami Lakes Florida 33016 —
Site 662 Miami Lakes Florida 33104 —
Site 609 Saint Cloud Florida 34769 —
Site 644 Council Bluffs Iowa 51503 —
Site 657 Boston Massachusetts 02115 —
Site 617 St Louis Missouri 63128 —
Site 602 Butte Montana 59701 —
Site 623 Las Vegas Nevada 89109 —
Site 630 Somers Point New Jersey 08244 —
Site 647 Jackson Heights New York 11372 —
Site 632 Mount Airy North Carolina 27030 —
Site 649 Toledo Ohio 43608 —
Site 607 Rapid City South Dakota 57702 —
Site 635 Jackson Tennessee 38305 —
Site 628 Smyrna Tennessee 37167 —
Site 633 Baytown Texas 77521 —
Site 605 Channelview Texas 77530 —
Site 625 Houston Texas 77008 —
Site 627 Houston Texas 77084 —
Site 634 Sugar Land Texas 77479 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02877927, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 30, 2018 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02877927 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →